LEXINGTON, Mass.—(BUSINESS WIRE)—Feb. 29, 2016—Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that David P. Southwell, President and Chief Executive Officer of Inotek, will present at Cowen and Company’s 36th Annual Health Care Conference on Monday, March 7th, 2016 at 2:00 ET at the Boston Marriott Copley Place Hotel in Boston. A live audio webcast of the presentation will be available on the Investors section of the company’s website, www.inotekpharma.com. A replay of the presentation will be archived on the Inotek website following the conference. About Inotek Pharmaceuticals Corporation Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is […]

Read more →